Navigation Links
Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
Date:10/26/2012

MIAMI, FL OCTOBER 26, 2012 Philippe Gnreux, MD was presented the TCT 2012 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The award is given each year to a promising researcher in the field of interventional cardiovascular medicine. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiology.

The award honors the memory of Thomas J. Linnemeier, MD, the former chief of the Indiana Heart Institute, senior vice president of New Ventures, and chief medical officer of Vascular Intervention at Guidant Corp. The purpose of the award, which is accompanied by a $10,000 grant, is to encourage the recipient to maintain a continued commitment and dedication to both patient care and academic research.

An outstanding young academician and a prolific writer, Dr. Philippe Gnreux is a practicing Interventional Cardiologist at Hpital du Sacr-Coeur de Montral. Dr. Gnreux also serves as the Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center where he leads the lab's coronary, peripheral, and structural imaging analyses and services. He received his medical degree from the Universit de Montral, Qubec, Canada, and is currently pursuing a PhD at Erasmus University in Rotterdam, The Netherlands. His research interests include coronary risk stratification/Syntax score, coronary physiology and imaging, percutaneous aortic valve replacement, transradial intervention, drug-eluting stent innovation, and medical simulation.

The winner was selected by Drs. Sheldon Goldberg, Howard C. Herrmann, John W. Hirshfeld Jr. and Robert L. Wilensky from Philadelphia. Gregg W. Stone, MD and Howard C. Hermann, MD jointly presented the award. Dr. Stone is Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Herrmann is Professor of Medicine and the Director of Interventional Cardiology and Cardiac Catheterization Labs at the Hospital of the University of Pennsylvania.

"Dr. Gnreux's tireless commitment to the dual tracks of cardiovascular research and patient care have established him as a rising star in the field, and he is well on his way to becoming a future leader in interventional cardiology," said Drs. Stone and Herrmann.

"We are extremely proud to honor Dr. Philippe Gnreux with the TCT 2012 Young Investigator Award for his exceptional academic achievements and superb clinical skills, as well as his dedication and passion for the field," Martin B. Leon, MD added. Dr. Leon is the Founder of CRF and Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Drs. Leon and Stone both serve as Co-Directors of the Medical Research and Education Division at CRF, and direct the annual TCT scientific sessions.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the XIMA trial presented at TCT 2012
2. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
3. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
4. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
5. Results of the PC trial presented at TCT 2012
6. Results of the POSEIDON trial presented at TCT 2012
7. 1-year results of ADAPT-DES presented at TCT 2012
8. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
9. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
10. Research presented at TCT 2012 will have significant impact on interventional cardiology
11. Typical IBD patients not represented in research studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... DC (PRWEB) , ... April ... ... Association (ATA) is thrilled to announce the ATA 2017 President’s Awards recipients, ... innovation and demonstrated superior healthcare delivery. , The ATA 2017 President’s ...
(Date:4/26/2017)... ... , ... Infertility may be a result of an underlying ... women become pregnant upon treating their diagnosis. , To properly diagnose ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
(Date:4/25/2017)... ... ... Lake Park Dental is now accepting new patients with crooked teeth who ... the help of this highly-effective, yet convenient system, patients can straighten their teeth and ... pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: